In particular, the decreased proteasomal degradation of PD-L1 together with the activation of a Rb/NF-κB-mediated transcriptional network have been identified as molecular events mediating the up-regulation of PD-L1 in cancer cells upon treatment with CDK4/6 inhibitors [166–168]. The gene discussed is CDK4; the disease is cancer.